Respiratory syncytial virus (RSV) infection is the major cause of severe respiratory illness in infants and young children, as well as in immune compromised individuals and the elderly. RSV infection of the lungs and respiratory tract leads to a range of illnesses varying from mild infection to life-threatening bronchiolitis and respiratory failure.
Recent epidemiological data indicates that over 3 million children under the age of 5 are hospitalized due to RSVrelated infections each year, with over 200,000 deaths annually. There is also a growing body of evidence suggesting that RSV is responsible for significant morbidity among the elderly and in adults with underlying chronic illness. Limited treatment options are driving therapeutic research programs worldwide, including 51 RSV vaccine candidates currently under development.
Despite over 50 years of research, there remains no licensed vaccine product and disease due to RSV infection remains an unmet medical need.
In vitro & in vivo models for RSV vaccine development can provide a critical component in development of anti-RSV antibodies, small molecules and vaccines. Learn how customized and high quality pre-clinical animal models and ex vivo readouts can support your anti-RSV biologics development from concept all the way to IND.